Show simple item record

dc.contributor.authorTelli, ML
dc.contributor.authorTolaney, SM
dc.contributor.authorShapiro, GI
dc.contributor.authorMiddleton, M
dc.contributor.authorLord, SR
dc.contributor.authorArkenau, HT
dc.contributor.authorTutt, A
dc.contributor.authorAbramson, V
dc.contributor.authorDean, E
dc.contributor.authorHaddad, TC
dc.contributor.authorWesolowski, R
dc.contributor.authorFerrer-Playan, J
dc.contributor.authorGoddemeier, T
dc.contributor.authorGrombacher, T
dc.contributor.authorDong, J
dc.contributor.authorFleuranceau-Morel, P
dc.contributor.authorDiaz-Padilla, I
dc.contributor.authorPlummer, R
dc.date.accessioned2022-05-17T14:37:25Z
dc.date.available2022-05-17T14:37:25Z
dc.date.issued2022-04-07
dc.identifier.citationNPJ breast cancer, 2022, 8 (1), pp. 45 - ?
dc.identifier.issn2374-4677
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5134
dc.identifier.eissn2374-4677
dc.identifier.eissn2374-4677
dc.identifier.doi10.1038/s41523-022-00406-0
dc.identifier.doi10.1038/s41523-022-00406-0
dc.description.abstractPlatinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) of the previously reported phase 1b trial (NCT02157792) is based on the recommended phase 2 dose of the combination of the ataxia-telangiectasia and Rad3-related (ATR) inhibitor berzosertib and cisplatin observed in patients with advanced solid tumors, including TNBC. Forty-seven patients aged ≥18 years with advanced TNBC received cisplatin (75 mg/m2; day 1) and berzosertib (140 mg/m2; days 2 and 9), in 21-day cycles. Berzosertib was well tolerated, with a similar toxicity profile to that reported previously for this combination. The overall response rate (90% confidence interval) was 23.4% (13.7, 35.8). No relevant associations were observed between response and gene alterations. Further studies combining ATR inhibitors with platinum compounds may be warranted in highly selected patient populations.
dc.formatElectronic
dc.format.extent45 - ?
dc.languageeng
dc.language.isoeng
dc.publisherNATURE PORTFOLIO
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titlePhase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
dc.typeJournal Article
dcterms.dateAccepted2022-02-16
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1038/s41523-022-00406-0
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2022-04-07
dc.relation.isPartOfNPJ breast cancer
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.publication-statusPublished
pubs.volume8
pubs.embargo.termsNot known
dc.contributor.icrauthorTutt, Andrew


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/